Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

In this prospective phase III trial, afatinib combined with paclitaxel improved progression-free survival and objective response, compared with single-agent chemotherapy, in patients with NSCLC who were clinically enriched for ErbB dependency having failed platinum-based chemotherapy, gefitinib/erlotinib and afatinib monotherapy after initial benefit on each tyrosine kinase inhibitor.

R. Greil | O. Popovych | C. Gridelli | Ying Cheng | J. Strausz | A. Dingemans | Keunchil Park | E. Felip | F. de Marinis | Yuh-Min Chen | G. Ceresoli | D. Planchard | J. Aerts | T. Hsia | J. Jassem | J. von Pawel | I. Bondarenko | Y. Humblet | A. Szczesna | Dong-Wan Kim | M. Schuler | Joo‐Hang Kim | J. Spicer | Ji-Youn Han | G. Zalcman | P. Mainwaring | S. Gans | Yilong Wu | P. Fournel | A. Onn | Y. Summers | C. Camps | C. Zhou | X. Liu | S. Lu | C. Chouaid | B. Garicochea | K. Prabhash | S. Qin | Yiping Zhang | Cheng Huang | Xiaoqing Liu | R. Gervais | T. Alanko | J. Stigt | U. Keilholz | R. Wiewrodt | F. Grossi | M. Platania | S. McLachlan | S. Popat | M. Gottfried | Caicun Zhou | Shun Lu | M. Cobo | A. Bearz | D-W. Kim | K. Park | P. Parente | J. Gurtler | J. Bennouna | G. Recondo | N. Karaseva | A. Każarnowicz | J. Zarbá | M. Faehling | R. Campelo | J. Cadranel | F. Bustin | J. Kim | S. Ignatius Ou | P. Bidoli | C. Ho | M. Pérol | T. Wehler | D. Galdermans | I. Polishchuk | C. Crombie | Jian-jin Huang | G. Cruciani | S. Orlov | C. Blajman | V. Sárosi | B. Coudert | Sankalpa Mitra | C. Underhill | C. Milandri | M. Migliorino | M. Zereu | P. Vercauter | E. Toy | P. Lianes | R. Shah | H. Riska | E. Laack | R. Nagarkar | Jin Wang | M. Lambrechts | P. Serwatowski | R. Hsieh | Xiaoyan Lin | J. G. González Larriba | Sang-We Kim | M. Rotarski | H. Dadhich | M. Jain | D. M. Sibilot | C. Chouaid | C. Bagnes | Y. Vinnyk | J. Feng | G. Chang | J. Thropay | V. Chand | G. Herder | Thomas Chang-Yao Tsao | M. Richardet | Pilar Garrido | J.C. Yang | P. Jaśkiewicz | J. Yang | J. Yang | Y-M. Chen | J. Feng | B. Wang | Z. Márk | Wu-Chou Su | D. Kim | W. R. Pantigoso | T. Talbot | F. Delgado | V. Lubennikov | G. A. Luna | L. Delval | Young-Chul Kim | K. Rohr | Ming-Shyan Huang | Chih‐Hsin Yang | Olga Ponomarova | M. Thomas | R. Huber | Sunil Upadhyay | S. Tehenes | L. Carestia | M. R. Migliorino | Nicolas Dickgreber | Ying-Huang Tsai | S. Stemmer | Emma Brown | J.-H. Kim | J-F Feng | S. Lu | Claudio Marcelo Martin | Cyntia Albuquerque Zadra | S. venkatesan | Lalit Sharma | José Luis Gonzalez Perez | Othon Padilla Baca | Jorge Fernando Salas Sánchez | Renzo Luzgardo Alvarez Barreda | Osbert Luis Mejia Palomino | Yuri Ragulin | Luis Meza | C. Martin | Emma L. Brown

[1]  J. Spicer,et al.  A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[3]  J. Neal,et al.  Rociletinib in EGFR-mutated non-small-cell lung cancer. , 2015, The New England journal of medicine.

[4]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[5]  H. Groen,et al.  Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. , 2014, Cancer discovery.

[6]  Keunchil Park,et al.  Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). , 2014 .

[7]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[8]  S. Digumarthy,et al.  Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. , 2013, The oncologist.

[9]  Y. Ichinose,et al.  LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  V. Gebski,et al.  Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. , 2013, Journal of the National Cancer Institute.

[12]  Huanyu Chen,et al.  Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis , 2013, Therapeutic innovation & regulatory science.

[13]  S. Kudoh,et al.  Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  C. Klein,et al.  Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker , 2012, Journal of Pharmacology and Experimental Therapeutics.

[15]  Yan Sun,et al.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.

[16]  C. Sima,et al.  Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design , 2011, Clinical Cancer Research.

[17]  N. Socci,et al.  Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.

[18]  M. Kris,et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Meyerson,et al.  BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.

[20]  B. Freidlin,et al.  Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  William Pao,et al.  Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus , 2007, Clinical Cancer Research.

[22]  A. Baum,et al.  567 POSTER Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents , 2006 .

[23]  Chris Williams.  Oncology , 1990, The Lancet.

[24]  P. Jänne,et al.  Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  L. Sequist,et al.  Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[26]  Horton,et al.  Annals of Oncology , 1991, Springer US.